Bengaluru-based global pharma maker of generic medicines across the US, Europe, Africa and emerging markets.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 90 | 90 | 90 | 90 | 92 | 92 | 92 | 92 |
| Reserves | 2.4k | 2.7k | 2.3k | 2.1k | 2.0k | 2.5k | 2.7k | 3.0k |
| Borrowings | 2.2k | 2.3k | 3.0k | 3.0k | 2.5k | 1.9k | 1.8k | 1.8k |
| Other Liabilities | 1.4k | 1.8k | 1.6k | 1.4k | 1.2k | 1.5k | 1.9k | 1.9k |
| Total Liabilities | 6.1k | 7.0k | 6.9k | 6.6k | 5.8k | 5.9k | 6.5k | 6.8k |
| AssetsFixed Assets | 2.1k | 2.2k | 2.3k | 2.3k | 1.9k | 1.9k | 2.1k | 2.1k |
| CWIP | 413 | 447 | 291 | 151 | 162 | 207 | 164 | 447 |
| Investments | 549 | 697 | 540 | 490 | 303 | 409 | 440 | 291 |
| Other Assets | 3.1k | 3.6k | 3.8k | 3.6k | 3.5k | 3.4k | 3.8k | 4.0k |
| Total Assets | 6.1k | 7.0k | 6.9k | 6.6k | 5.8k | 5.9k | 6.5k | 6.8k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 60 | 205 | 481 | -258 | 44 | 701 | 684 | 703 |
| Cash from Investing | -145 | 1.3k | -522 | -119 | 302 | -150 | -90 | -173 |
| Cash from Financing | 194 | -1.7k | -16 | 421 | -214 | -693 | -643 | -453 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -256 | 58 | 188 | -326 | -43 | 672 | 505 | 291 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
STAR · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.